Full Press Release Details
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will present four scientific posters highlighting advances of Alzheimer’s clinical program and pharmacokinetic characterization of its lead drug candidate, buntanetap.
Presentation details:
Poster #1: Design of Phase III study testing buntanetap efficacy in early Alzheimer’s patients based on the insights from previous studies.
Presenter: Cheng Fang, Ph.D., Senior Vice President, Research & Development.
Poster #2: A dual 6-month & 18-month prospective, randomized, placebo-controlled, double-blind, pivotal clinical trial investigating efficacy and safety of buntanetap in early Alzheimer's patients.
Presenter: Sarah MacCallum, Director of Clinical Operations.
Poster #3: Advancing buntanetap: comparative pharmacokinetic characterization of the original semi-crystalline with the novel crystalline form in animals and humans.
Presenter: Alexander Morin, Ph.D., Director of Strategic Communications.
Poster #4: Pharmacokinetic characterization of buntanetap in plasma of patients with early Alzheimer’s and Parkinson’s diseases.
Presenter: Matthew Peterson, Ph.D., Senior Clinical Scientist.
The AAIC 2025 is the world’s largest meeting dedicated to advancing the science and clinical practice of dementia. Each year, the conference brings together researchers, clinicians, and professionals from around the globe to share cutting-edge discoveries and clinical insights aimed at improving the diagnosis, treatment, and care of individuals affected by AD and other dementias.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
101 Lindenwood Drive
Alexander Morin, Ph.D.
Director, Strategic Communications